Lycia Therapeutics has grabbed a $70 million series B for its next-generation degradation approach to zero in on the untapped extracellular proteome that could target a host of diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,